[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637359":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":12,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":12,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":74,"whyStopped":12,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Jinling Hospital, China","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","NO_INTERVENTION","patients received placebo combined with anti-PD-1 therapy and chemotherapy, without additional sodium propionate intervention.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Sodium propionate","EXPERIMENTAL","on the basis of anti-PD-1 therapy combined with chemotherapy, patients were additionally given oral sodium propionate capsules at a dose of 500 mg per capsule, one capsule twice a week, for a total intervention period of 12 weeks.",[18],"Dietary Supplement: Sodium propionate",[20],{"type":21,"name":14,"description":16,"armGroupLabels":22,"otherNames":23},"DIETARY_SUPPLEMENT",[14],[24],"Propionic acid",[26],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Xinying Wang, MD","CONTACT","+86 13913028866","wangxinying@nju.edu.cn",[32],{"facility":33,"status":12,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Xinying Wang","Nanjing","Jiangsu","210002","China","CN",{"type":40,"coordinates":41},"Point",[42,43],118.77778,32.06167,{"lat":43,"lon":42},[46],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Wang Xinying","prof","100637359","a-study-on-the-efficacy-of-sodium-propionate-combined-with-anti-pd-1-immunotherapy-in-gastric-cancer-100637359",false,"NCT07615907","A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer","Sodium Propionate Combined With Anti-PD-1 Immunotherapy on Tumor Efficacy in Gastric Cancer Patients","PAPGC","Inclusion Criteria:\n\n* Subjects voluntarily participated in the trial and signed the informed consent form;\n* Aged ≥ 18 years and \\\u003C 80 years, regardless of gender;\n* Stable vital signs;\n* Patients with gastric adenocarcinoma confirmed by gastroscopic biopsy;\n* Tumors judged as unresectable by attending physicians;\n* Receiving anti-PD-1 therapy combined with chemotherapy as first-line treatment;\n* No history of allergic diseases and non-allergic constitution;\n* No history of drug abuse;\n* Non-pregnant and non-lactating females (applicable to male subjects as well);\n* No participation in any drug clinical trial (including investigational drugs of this trial) within 3 months prior to enrollment.\n\nExclusion Criteria:\n\n* Failure to meet the inclusion criteria, or individuals deemed inappropriate for trial participation by investigators;\n* Concurrent primary malignant tumors at other sites;\n* Poor general condition, severe infection, respiratory insufficiency, or other conditions leading to inability to cooperate with the trial;\n* Patients with mental disorders, consciousness disturbance, or poor treatment compliance;\n* Suspected or confirmed history of drug abuse;\n* Immunodeficiency, or long-term use of immunosuppressants and glucocorticoids;\n* Pregnant or lactating women;\n* Sponsors, investigators directly involved in this trial, and their immediate family members;\n* Individuals unsuitable for enrollment for any reason as judged by the investigator.","ALL","18 Years","80 Years",{"count":63,"type":64},20,"ESTIMATED","INTERVENTIONAL",[67],"NA","Eligible patients were randomized into two groups: the sodium propionate group and the control group. In the control group, patients received placebo combined with anti-PD-1 therapy plus chemotherapy without additional sodium propionate intervention. In the sodium propionate group, on the basis of anti-PD-1 therapy combined with chemotherapy, patients were additionally administered oral sodium propionate capsules at a dose of 500 mg (1 capsule) twice weekly, with a total intervention duration of 12 weeks. The primary and secondary outcome indicators will be collected for subsequent analysis.",[70],"Gastric Cancer (GC)",[72,14,73],"Gastric cancer","Immunotherapy","NOT_YET_RECRUITING","2026-05-25",{"date":77,"type":78},"2026-05-29","ACTUAL",{"date":80,"type":64},"2026-05-30",{"date":82,"type":64},"2027-08-30",{"name":5,"class":6},1]